Pharnext SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pharnext SA - overview
Established
2007
Location
Paris, -, France
Primary Industry
Pharmaceuticals
About
Founded in 2007 and based in France, Pharnext SA is a biopharmaceutical company that focuses on developing innovative drug combinations based on genomic big data and artificial intelligence for the treatment of neurological diseases. Its products include PLEODRUG PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A) and PLEODRUG PXT864 for the treatment of Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS or Charcot's disease).
Current Investors
Truffle Capital, Parinvest, La Financière Gaspard
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.pharnext.com
Verticals
Artificial Intelligence, Big Data
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.